Plain-English translation of NCT07468708 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is evaluating a new imaging tracer called , which is designed to help doctors detect prostate cancer more accurately. Researchers want to understand how safe this medication is, where it travels in the body, and how well it works at finding prostate cancer. The study will compare this new tracer with an existing prostate cancer imaging tracer to see if it offers any advantages.
Current prostate cancer imaging tools have limitations, and doctors need better ways to detect and locate prostate cancer in patients. This trial aims to determine whether this new medication could become a safer and more effective diagnostic tool for patients who need prostate cancer imaging.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive an injection of the new imaging tracer and then undergo PET/CT scans (imaging tests that show how the tracer moves through your body). Depending on which group you're in, you may also receive a second imaging scan using a standard prostate cancer tracer so researchers can compare the two. The study will evaluate the safety of the medication and measure radiation exposure to help ensure it's safe for future patients.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China